Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michela Magnano

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Acta Dermato-Venereologica|May 18, 2017
Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian ExperienceFederico Bardazzi, Michela Magnano, Anna Campanati, et al.
Italian Journal of Dermatology and Venereology|November 24, 2023
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observationFlavia Manzo Margiotta, Alessandra Michelucci, Eugenio Capalbo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 16, 2023
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective studyMartina Dragotto, Eugenio Capalbo, Alessandra Cartocci, et al.
Italian Journal of Dermatology and Venereology|November 7, 2024
Risankizumab in very elderly patients in real-world practiceElisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Dermatology Practical & Conceptual|November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2020
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based studySatveer K Mahil, Nick Dand, Kayleigh J Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre studyRiccardo Balestri, Giulia Odorici, Michela Magnano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week resultsBianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Acta Dermato-Venereologica|May 18, 2017
Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian ExperienceFederico Bardazzi, Michela Magnano, Anna Campanati, et al.
Italian Journal of Dermatology and Venereology|November 24, 2023
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observationFlavia Manzo Margiotta, Alessandra Michelucci, Eugenio Capalbo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 16, 2023
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective studyMartina Dragotto, Eugenio Capalbo, Alessandra Cartocci, et al.
Italian Journal of Dermatology and Venereology|November 7, 2024
Risankizumab in very elderly patients in real-world practiceElisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Dermatology Practical & Conceptual|November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2020
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based studySatveer K Mahil, Nick Dand, Kayleigh J Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre studyRiccardo Balestri, Giulia Odorici, Michela Magnano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week resultsBianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 7